Literature DB >> 3752110

Stability of vancomycin hydrochloride in 5% dextrose and 0.9% sodium chloride injections.

V Das Gupta, K R Stewart, S Nohria.   

Abstract

The stability of vancomycin hydrochloride mixed with 5% dextrose and 0.9% sodium chloride injections was studied. Vancomycin hydrochloride powder was mixed with each of the two diluents in final concentrations of 5 mg/mL. Duplicate samples of each admixture were divided into four parts and stored at 24 degrees C in glass and in plastic i.v. bags for 17 days and at 5 degrees C and -10 degrees C in glass for 63 days. To additional samples, hydrochloric acid or phosphate buffer was added; these were stored at 24 degrees C for 17 days. At various storage times, clarity and pH of the samples were recorded and vancomycin concentrations were measured in triplicate by high-performance liquid chromatography. Except for the buffered samples, all solutions remained clear and pH was unchanged. Vancomycin concentrations decreased less than 6% during 17 days at room temperature. In the refrigerated and frozen samples, vancomycin concentrations decreased less than 1% throughout the study. Vancomycin hydrochloride is stable in admixtures with 5% dextrose injection and 0.9% sodium chloride injection for 17 days at 24 degrees C and for 63 days at 5 degrees C and -10 degrees C.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3752110

Source DB:  PubMed          Journal:  Am J Hosp Pharm        ISSN: 0002-9289


  3 in total

1.  Constant rate infusion of vancomycin in premature neonates: a new dosage schedule.

Authors:  F Pawlotsky; A Thomas; M F Kergueris; T Debillon; J C Roze
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

2.  Stability of commonly used antibiotic solutions in an elastomeric infusion device.

Authors:  Scott E Walker; John Iazzetta; Shirley Law; Kristof Biniecki
Journal:  Can J Hosp Pharm       Date:  2010-05

Review 3.  Vancomycin Dosing and Monitoring: Critical Evaluation of the Current Practice.

Authors:  Fawzy Elbarbry
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-06       Impact factor: 2.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.